サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1720806

成長ホルモン欠乏症の世界市場レポート 2025年

Growth Hormone Deficiency Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
成長ホルモン欠乏症の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

成長ホルモン欠乏症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.9％で54億2,000万米ドルに成長します。予測期間中の成長は、遺伝性疾患の有病率の増加、戦略的イニシアチブの増加、研究開発努力の強化、Gh疾患の罹患率の増加、臨床検査数の拡大に起因すると考えられます。予測期間における主要動向としては、技術の進歩、治療選択肢の拡大、診断技術の改善、最近の動向、バイオテクノロジーの進歩などが挙げられます。

遺伝性疾患の有病率の増加が成長ホルモン欠乏症市場の拡大を牽引すると予想されます。遺伝性疾患は、個人のDNAの異常や変異に起因する病状であり、遺伝性または自然発生のいずれでもあります。診断技術の進歩、認知度の向上、妊産婦年齢の上昇、変異を引き起こす環境要因、人口増加、罹患者の生存率の向上など、いくつかの要因が蔓延率の上昇に寄与しています。成長ホルモン欠乏症治療は、特定の遺伝的疾患に伴う成長関連の合併症の管理に役立ちます。例えば、英国の政府部門である保健社会医療省（DHSC）が2022年12月に発表した報告書によると、2022年10月には約3万3,000の全ゲノム相当の配列が決定され、平均診断収率は32％で、特定の疾患では61％に上昇しました。その結果、遺伝性疾患の有病率の増加が成長ホルモン欠乏症市場の成長に拍車をかけています。

成長ホルモン欠乏症市場の主要企業は、小児成長ホルモン欠乏症（GHD）に対する非修飾ソマトロピンなどの革新的治療の開拓に注力しています。非修飾ソマトロピンは、毎日のGHD治療に使用される成長ホルモンと同じものであるが、スカイトロファで週1回投与できるように製剤化されたものです。例えば、2023年9月、デンマークを拠点とするバイオ医薬品会社Ascendis Pharma A/Sは、小児GHDの週1回治療としてSKYTROFA（lonapegsomatropin）を発売しました。この技術革新により、利便性が向上し、服薬アドヒアランスが改善され、従来型成長ホルモン連日投与療法と比較して治療成績が向上する可能性があります。小児GHDの週1回治療として初めてFDAに承認された唯一の薬剤であり、内分泌学と小児医療における大きな進歩を意味します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界の成長ホルモン欠乏症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の成長ホルモン欠乏症市場：成長率分析
  • 世界の成長ホルモン欠乏症市場の実績：規模と成長、2019～2024年
  • 世界の成長ホルモン欠乏症市場の予測：規模と成長、2024～2029年、2034年
  • 世界の成長ホルモン欠乏症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の成長ホルモン欠乏症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 小児成長ホルモン欠乏症
  • 成人成長ホルモン欠乏症
  • 世界の成長ホルモン欠乏症市場治療別、実績と予測、2019～2024年、2024～2029年、2034年
  • 薬剤療法
  • 組み換えヒト成長ホルモン
  • ヒト下垂体抽出物
  • 手術
  • 世界の成長ホルモン欠乏症市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
  • 静脈内
  • 筋肉内
  • その他
  • 世界の成長ホルモン欠乏症市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院薬局
  • オンライン薬局
  • 小売薬局
  • 世界の成長ホルモン欠乏症市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 在宅医療
  • 専門クリニック
  • その他
  • 世界の成長ホルモン欠乏症市場、小児成長ホルモン欠乏症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 特発性成長ホルモン欠乏症
  • 遺伝的成長ホルモン欠乏症
  • 成長ホルモン欠乏症を取得しました
  • 世界の成長ホルモン欠乏症市場、成人成長ホルモン欠乏症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • 一次成長ホルモン欠乏症
  • 二次成長ホルモン欠乏症

第7章 地域別・国別分析

  • 世界の成長ホルモン欠乏症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界の成長ホルモン欠乏症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 成長ホルモン欠乏症市場：競合情勢
  • 成長ホルモン欠乏症市場：企業プロファイル
    • Pfizer Inc.
    • F. Hoffmann-La Roche Ltd.
    • Merck KGaA
    • AbbVie Inc.
    • Eli Lilly and Company

第31章 その他の大手企業と革新的企業

  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Genentech Inc.
  • Ipsen Biopharmaceuticals Inc.
  • Opko Health Inc.
  • JCR Pharmaceuticals Co. Ltd.
  • Ferring Pharmaceuticals Inc.
  • Ascendis Pharma A/S
  • Rani Therapeutics Inc.
  • AnkeBio Co. Ltd.
  • Aeterna Zentaris Inc.
  • Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.
  • Versartis Inc.
  • I-Mab Biopharma Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • 成長ホルモン欠乏症市場、2029年：新たな機会を提供する国
  • 成長ホルモン欠乏症市場、2029年：新たな機会を提供するセグメント
  • 成長ホルモン欠乏症市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34063

Growth hormone deficiency (GHD) is a medical condition in which the pituitary gland does not produce enough growth hormone (GH). This deficiency leads to stunted growth and development in children and various metabolic issues in adults. Growth hormone deficiency can be congenital (present at birth) or acquired due to injury, tumors, infections, or other medical conditions affecting the pituitary gland.

The primary types of growth hormone deficiency are pediatric growth hormone deficiency and adult growth hormone deficiency. Pediatric growth hormone deficiency focuses on children with inadequate growth hormone production, resulting in stunted growth and delayed development. Treatments involved are pharmacological therapy, recombinant human growth hormone, human pituitary gland extracts, and surgery. The various routes of administration include intravenous, intramuscular, and others. They are distributed through several channels, such as hospital pharmacy, online pharmacy, and retail pharmacy, and are used by multiple end users, including hospitals, home care, specialty clinics, and others.

The growth hormone deficiency market research report is one of a series of new reports from The Business Research Company that provides growth hormone deficiency market statistics, including the growth hormone deficiency industry global market size, regional shares, competitors with the growth hormone deficiency market share, detailed growth hormone deficiency market segments, market trends, and opportunities, and any further data you may need to thrive in the growth hormone deficiency industry. This growth hormone deficiency market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth hormone deficiency market size has grown strongly in recent years. It will grow from $4.06 billion in 2024 to $4.31 billion in 2025 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to the rising number of strategic initiatives, increasing incidences of brain tumors, growing demand for hormone therapies, increased elderly population, and rising government funding for healthcare.

The growth hormone deficiency market size is expected to see strong growth in the next few years. It will grow to $5.42 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth during the forecast period can be attributed to the increasing prevalence of genetic disorders, the rising number of strategic initiatives, enhanced research and development efforts, the growing morbidity of Gh disease, and the expanding number of clinical trials. Key trends in the forecast period include technological advancements, the expansion of treatment options, improvements in diagnostic techniques, recent developments, and progress in biotechnology.

The increasing prevalence of genetic disorders is expected to drive the expansion of the growth hormone deficiency market. Genetic disorders are medical conditions resulting from abnormalities or mutations in an individual's DNA, either inherited or occurring spontaneously. Several factors contribute to their rising prevalence, including advancements in diagnostic technology, increased awareness, rising maternal age, environmental factors causing mutations, population growth, and improved survival rates for affected individuals. Growth hormone deficiency treatments help manage growth-related complications associated with certain genetic conditions. For instance, according to a report published in December 2022 by the Department of Health & Social Care (DHSC), a UK-based government department, approximately 33,000 whole genome equivalents were sequenced in October 2022, with an average diagnostic yield of 32%, rising to 61% in specific conditions. As a result, the increasing prevalence of genetic disorders is fueling the growth of the growth hormone deficiency market.

Leading companies in the growth hormone deficiency market are focusing on developing innovative treatments, such as unmodified somatropin, for pediatric growth hormone deficiency (GHD). Unmodified somatropin is the same growth hormone used in daily GHD treatments but formulated for once-weekly administration with Skytrofa. For example, in September 2023, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, launched SKYTROFA (lonapegsomatropin) as a once-weekly treatment for pediatric GHD. This innovation enhances convenience, improves adherence, and offers potentially better treatment outcomes compared to traditional daily growth hormone therapies. As the first and only FDA-approved once-weekly treatment for pediatric GHD, it represents a significant advancement in endocrinology and pediatric care.

In February 2022, Pfizer Inc., a US-based pharmaceutical company, partnered with OPKO Health Inc. to advance the treatment of pediatric growth hormone deficiency (GHD). Through this collaboration, Pfizer and OPKO Health aim to develop and commercialize NGENLA (somatrogon), a next-generation long-acting recombinant human growth hormone that reduces the injection frequency from once daily to once weekly. This approach improves treatment adherence, minimizes the burden of disease management, and enhances the overall quality of life for children and adolescents with GHD. OPKO Health Inc. is a US-based company specializing in the development and commercialization of treatments for growth hormone deficiency.

Major players in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.

North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in growth hormone deficiency report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the growth hormone deficiency market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The growth hormone deficiency market consists of revenues earned by entities by providing services such as diagnostic services, treatment services, and specialized services. The market value includes the value of related goods sold by the service provider or included within the service offering. The growth hormone deficiency market consists of sales of recombinant human growth hormones, long-acting growth hormones and combination therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Growth Hormone Deficiency Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on growth hormone deficiency market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for growth hormone deficiency ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The growth hormone deficiency market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Pediatric Growth Hormone Deficiency; Adult Growth Hormone Deficiency
  • 2) By Treatment: Pharmacological Therapy; Recombinant Human Growth Hormone; Human Pituitary Gland Extracts; Surgery
  • 3) By Route Of Administration: Intravenous; Intramuscular; Other Routes Of Administration
  • 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
  • 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
  • Subsegments:
  • 1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency; Genetic Growth Hormone Deficiency; Acquired Growth Hormone Deficiency
  • 2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency; Secondary Growth Hormone Deficiency
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck KGaA; AbbVie Inc.; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Growth Hormone Deficiency Market Characteristics

3. Growth Hormone Deficiency Market Trends And Strategies

4. Growth Hormone Deficiency Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Growth Hormone Deficiency Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Growth Hormone Deficiency PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Growth Hormone Deficiency Market Growth Rate Analysis
  • 5.4. Global Growth Hormone Deficiency Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Growth Hormone Deficiency Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Growth Hormone Deficiency Total Addressable Market (TAM)

6. Growth Hormone Deficiency Market Segmentation

  • 6.1. Global Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pediatric Growth Hormone Deficiency
  • Adult Growth Hormone Deficiency
  • 6.2. Global Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmacological Therapy
  • Recombinant Human Growth Hormone
  • Human Pituitary Gland Extracts
  • Surgery
  • 6.3. Global Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Intravenous
  • Intramuscular
  • Other Routes Of Administration
  • 6.4. Global Growth Hormone Deficiency Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • 6.5. Global Growth Hormone Deficiency Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Other End Users
  • 6.6. Global Growth Hormone Deficiency Market, Sub-Segmentation Of Pediatric Growth Hormone Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Idiopathic Growth Hormone Deficiency
  • Genetic Growth Hormone Deficiency
  • Acquired Growth Hormone Deficiency
  • 6.7. Global Growth Hormone Deficiency Market, Sub-Segmentation Of Adult Growth Hormone Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Primary Growth Hormone Deficiency
  • Secondary Growth Hormone Deficiency

7. Growth Hormone Deficiency Market Regional And Country Analysis

  • 7.1. Global Growth Hormone Deficiency Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Growth Hormone Deficiency Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Growth Hormone Deficiency Market

  • 8.1. Asia-Pacific Growth Hormone Deficiency Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Growth Hormone Deficiency Market

  • 9.1. China Growth Hormone Deficiency Market Overview
  • 9.2. China Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Growth Hormone Deficiency Market

  • 10.1. India Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Growth Hormone Deficiency Market

  • 11.1. Japan Growth Hormone Deficiency Market Overview
  • 11.2. Japan Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Growth Hormone Deficiency Market

  • 12.1. Australia Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Growth Hormone Deficiency Market

  • 13.1. Indonesia Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Growth Hormone Deficiency Market

  • 14.1. South Korea Growth Hormone Deficiency Market Overview
  • 14.2. South Korea Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Growth Hormone Deficiency Market

  • 15.1. Western Europe Growth Hormone Deficiency Market Overview
  • 15.2. Western Europe Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Growth Hormone Deficiency Market

  • 16.1. UK Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Growth Hormone Deficiency Market

  • 17.1. Germany Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Growth Hormone Deficiency Market

  • 18.1. France Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Growth Hormone Deficiency Market

  • 19.1. Italy Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Growth Hormone Deficiency Market

  • 20.1. Spain Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Growth Hormone Deficiency Market

  • 21.1. Eastern Europe Growth Hormone Deficiency Market Overview
  • 21.2. Eastern Europe Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Growth Hormone Deficiency Market

  • 22.1. Russia Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Growth Hormone Deficiency Market

  • 23.1. North America Growth Hormone Deficiency Market Overview
  • 23.2. North America Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Growth Hormone Deficiency Market

  • 24.1. USA Growth Hormone Deficiency Market Overview
  • 24.2. USA Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Growth Hormone Deficiency Market

  • 25.1. Canada Growth Hormone Deficiency Market Overview
  • 25.2. Canada Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Growth Hormone Deficiency Market

  • 26.1. South America Growth Hormone Deficiency Market Overview
  • 26.2. South America Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Growth Hormone Deficiency Market

  • 27.1. Brazil Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Growth Hormone Deficiency Market

  • 28.1. Middle East Growth Hormone Deficiency Market Overview
  • 28.2. Middle East Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Growth Hormone Deficiency Market

  • 29.1. Africa Growth Hormone Deficiency Market Overview
  • 29.2. Africa Growth Hormone Deficiency Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Growth Hormone Deficiency Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Growth Hormone Deficiency Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Growth Hormone Deficiency Market Competitive Landscape And Company Profiles

  • 30.1. Growth Hormone Deficiency Market Competitive Landscape
  • 30.2. Growth Hormone Deficiency Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis

31. Growth Hormone Deficiency Market Other Major And Innovative Companies

  • 31.1. Novo Nordisk A/S
  • 31.2. Teva Pharmaceutical Industries Ltd.
  • 31.3. Sandoz International GmbH
  • 31.4. Genentech Inc.
  • 31.5. Ipsen Biopharmaceuticals Inc.
  • 31.6. Opko Health Inc.
  • 31.7. JCR Pharmaceuticals Co. Ltd.
  • 31.8. Ferring Pharmaceuticals Inc.
  • 31.9. Ascendis Pharma A/S
  • 31.10. Rani Therapeutics Inc.
  • 31.11. AnkeBio Co. Ltd.
  • 31.12. Aeterna Zentaris Inc.
  • 31.13. Zhongshan Sinobioway Hygene Biomedicine Co. Ltd.
  • 31.14. Versartis Inc.
  • 31.15. I-Mab Biopharma Co. Ltd.

32. Global Growth Hormone Deficiency Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Growth Hormone Deficiency Market

34. Recent Developments In The Growth Hormone Deficiency Market

35. Growth Hormone Deficiency Market High Potential Countries, Segments and Strategies

  • 35.1 Growth Hormone Deficiency Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Growth Hormone Deficiency Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Growth Hormone Deficiency Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer